Ken Griffin Fsd Pharma Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$1.07 - $1.6 $9,737 - $14,560	9,100 Added 65.94%	22,900 $27,000
Q2 2023 Aug 14, 2023	SELL	$0.99 - $2.04 $9,801 - $20,196	-9,900 Reduced 41.77%	13,800 $15,000
Q1 2023 May 15, 2023	SELL	$0.77 - $1.81 $18,172 - $42,716	-23,600 Reduced 49.89%	23,700 $36,000
Q4 2022 Feb 14, 2023	BUY	$0.73 - $58.49 $15,914 - $1.28 Million	21,800 Added 85.49%	47,300 $37,000
Q3 2022 Nov 14, 2022	SELL	$0.78 - $61.1 $11,076 - $867,620	-14,200 Reduced 35.77%	25,500 $21,000

Ticker HUGE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 38,218,100
Market Cap $152M
Description
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.